<DOC>
	<DOCNO>NCT01313390</DOCNO>
	<brief_summary>RATIONALE : Everolimus may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether give everolimus together docetaxel effective give docetaxel alone treat patient head neck cancer . PURPOSE : This phase I/II trial study side effect best dose everolimus give together docetaxel treat patient recurrent , locally advanced , metastatic head neck cancer .</brief_summary>
	<brief_title>Everolimus Docetaxel Treating Patients With Recurrent , Locally Advanced , Metastatic Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine safety tolerability combination everolimus docetaxel treat patient recurrent , locally advanced metastatic squamous cell carcinoma head neck . ( Phase I ) - To determine maximum-tolerated dose recommend phase II dose everolimus combine docetaxel patient . ( Phase I ) - To examine response rate patient receive combination docetaxel everolimus receive docetaxel alone . ( Phase II ) Secondary - To investigate possible pharmacokinetic interaction docetaxel everolimus patient . ( Phase I ) - To investigate effect everolimus downstream target mTOR tumor patient . ( Phase I ) - To examine time progression docetaxel everolimus patient . ( Phase II ) - To perform pilot study attempt identify predictor response , include evaluation EGFR family member expression , mutation , amplification . ( Phase II ) - To attempt identify downstream target EGFR pathway include phosphorylation S6 phosphorylation AKT . ( Phase II ) OUTLINE : This multicenter , phase I , dose-escalation study everolimus docetaxel follow randomized phase II study . - Phase I : Patients receive docetaxel IV 1 hour day 1 escalating dos oral everolimus day 1 , 8 , 15 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion 6 course therapy , patient may continue receive everolimus weekly single agent evidence progressive disease . - Phase II : Patients randomize 1 2 treatment arm : - Arm A : Patients receive docetaxel IV 1 hour day 1.Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients progressive disease eligible cross everolimus arm investigator 's discretion . - Arm B : Patients receive docetaxel arm A oral everolimus ( dose determine phase I portion study ) day 1 , 8 , 15 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion combination therapy , patient may continue receive maintenance everolimus weekly , investigator 's discretion . Blood sample collect pharmacokinetic monitoring phase I study . Tissue sample collect baseline periodically study biomarker laboratory analysis . After completion study treatment , patient follow every 3 month least 1 year . Peer Reviewed Funded Endorsed Cancer Research UK . PROJECTED ACCRUAL : Approximately 18 patient accrued phase I total 100 patient accrue phase II study .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma head neck Locally advance metastatic disease No patient locally advanced disease radiotherapy indicate Recurrent disease Incurable disease Measurable disease RECIST criterion Recurrent disease within prior radiation field consider measurable Patients may receive 1 line prior chemotherapy ( taxane ) locally advanced metastatic disease Patients may receive prior radiation therapy locally advance metastatic disease ( must complete radiotherapy &gt; 6 month recruitment ) No disease relapse within 6 month radiotherapy No evidence central nervous system metastases PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy ≥ 12 week Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL Urea creatinine normal Serum bilirubin normal AST ALT ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase &lt; 2.5 time ULN Negative pregnancy test Not pregnant nursing Fertile patient must use effective contraception 3 month ( female ) 2 month ( male ) last dose study treatment No uncontrolled infection No mental condition render patient unable understand nature , scope , possible consequence study No prior malignancy likely interfere patient 's ability comply treatment and/or follow PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy cancer , except head neck cancer No prior taxane No prior therapy erbB inhibitor ( except cetuximab give radiotherapy , indicate treatment algorithm ) More 6 month since prior radiotherapy locally advance metastatic disease At least 4 week since prior investigational drug No concurrent use drug know inhibit CYP3A4 ( except dexamethasone ) , block Pglycoprotein , include grapefruit juice No concurrent chemotherapy , immunotherapy , hormonal cancer therapy , radiotherapy , experimental medication No concurrent live vaccine everolimus therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>stage III salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>tongue cancer</keyword>
</DOC>